Exelixis (NASDAQ: EXEL) is, without question, one of the hottest biotech stocks around. Shares have nearly quintupled in value over the last 12 months. So far in 2017, Exelixis stock is up more than 40%.
But this tremendous success now raises questions about how much farther Exelixis’ share price can increase from this point. Is it time for investors to move on?
Image source: Getty Images.